Summary
Signal counts
Assets tracked: 4
Watchlist assets: 1
Registry stop assets: 1
Sponsor overview
Eli Lilly and Company
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00781911 | https://clinicaltrials.gov/study/NCT00520481 | https://clinicaltrials.gov/study/NCT00079872 | https://clinicaltrials.gov/study/NCT00550173 | https://clinicaltrials.gov/study/NCT00383266 | https://clinicaltrials.gov/study/NCT00529100
Assets
Linked programs
- Cixutumumab: Low Signal (0/5)
- IMC-A12 (Cixutumumab): Low Signal (1/5)
- Pemetrexed: Registry Stop Signal (5/5)
- Pemetrexed Phase 1: Low Signal (0/5)